Chemerin receptor blockade improves vascular function in diabetic obese mice via redox-sensitive-and Akt-dependent pathways.
INTRODUCTION 47 48
Obesity, characterized by hypertrophy and hyperplasia of adipose tissue, is a critical risk 49 factor for hypertension, dyslipidaemia, cardiovascular disease, and type 2 diabetes (T2D) (33) . 50
Obesity is also linked to decreased sensitivity to the biological actions of insulin, a condition 51 identified as insulin resistance (48) . In addition to its central energy storage function, adipose 52 tissue secretes several bioactive hormones and cytokines, called adipokines (51). Adipokines 53 have autocrine/paracrine effects that influence not only adipose tissue development and function 54 (21), but also energy homeostasis, glucose and lipid metabolism, food intake, inflammation, and 55 vascular function (26, 51) . Dysregulation of adipokine production and secretion contribute to the 56 pathogenesis of obesity and its associated vascular complications (51) . 57
Chemerin, also known as retinoic acid receptor responder protein 2 (RARRES2) or 58 tazarotene-induced gene 2 protein (TIG2), is highly expressed in the placenta, liver, and white 59 adipose tissue (WAT), with a lower expression in tissues such as lung, brown adipose tissue, 60 heart, ovary, kidney, skeletal muscle and pancreas (4, 14) . It is secreted as an 18-kDa inactive 61 pro-protein and undergoes extracellular serine protease cleavage to generate the 16-kDa active 62 chemerin (50). Chemerin is a chemoattractant protein that binds to the G protein-coupled 63 receptor CMKLR1 (chemokine-like receptor 1), also known as ChemR23, which is expressed in 64 macrophages, dendritic cells, adipocytes (50) as well as in endothelial and vascular smooth 65 muscle cells (VSMC), as recently reported (46) . Although chemerin also activates the G protein-66 coupled receptor 1 (GPR1) with similar affinity to CMKLR1 and is a ligand for a third receptor, 67 chemokine receptor-like 2 (CCRL2), which does not seem to activate intracellular responses, 68 essentially all known responses to chemerin have been attributed to the activation of ChemR23 69
(1). 70
Chemerin is currently described as a biomarker for adiposity in humans. Circulating 71 chemerin levels were shown to be strongly associated with multiple components of metabolic 72 syndrome, including body mass index (BMI), triglycerides, high-density lipoprotein cholesterol 73
(HDL-C) and hypertension (4), and are also linked to adipogenesis (15, 35) . Circulating 74 chemerin levels are increased in numerous diseases associated with chronic inflammation (47) . 75
Serum levels of chemerin correlate with levels of proinflammatory cytokines, such as tumor 76 necrosis factor-α (TNF-α), interleukin 6 (IL-6) and C reactive protein (CRP) (24, 47) . 77
Importantly, ChemR23 knockout mice present reduced adiposity and body mass (9) and 78 chemerin levels are reduced by weight loss and fat reduction (9). Chemerin expression is 79 upregulated in adipocytes of diet-induced obese mice (10, 34) . Increased chemerin expression in 80 WAT, skeletal muscle, and liver has been reported in mouse models of obesity/diabetes and 81 chemerin exacerbates glucose intolerance, lowers serum insulin levels, and decreases tissue 82 glucose uptake in obese diabetic db/db mice (10, 35) . More recently, it has also been 83 demonstrated an important role for reactive oxygen species (ROS) in chemerin signalling in 84 vascular cells. Particularly chemerin, through ROS, stimulates mitogenic and pro-inflammatory 85 signalling pathways promoting vascular damage and remodelling (45) . 86
Although chemerin has been shown to impair insulin signalling and to induce insulin 87 resistance in skeletal muscle cells (41) and cardiomyocytes (52), the role of chemerin in vascular 88 insulin resistance particularly in the context of diabetes, has not been fully elucidated. Therefore, 89 the present study aimed to determine whether chemerin influences vascular insulin signalling and 90 whether there is interplay between chemerin/ChemR23, insulin resistance and vascular 91 complications associated with T2D. We hypothesized that chemerin, Ten to twelve weeks-old male C57BL/6J, lean non-diabetic db/m and obese diabetic 106 db/db mice were housed in individual cages in a room with controlled humidity and temperature 107
(22 • C -24 • C), and light/dark cycles of 12 hours (h). Animals had free access to food and tap 108 water. Animals were treated with vehicle (PEG400/cremophor) or CCX832, a ChemR23 109 antagonist, (a gift from ChemoCentryx, Inc., Mountain View, CA, USA) (75 mg/kg/day, for 3 110 weeks, by oral gavage). Animals were separated into 4 groups: db/m + vehicle, db/m + CCX832, 111 db/db + vehicle and db/db + CCX832. In initial experiments, in order to confirm that the vehicle 112 had no effects itself, two additional groups were included and maintained for the same three 113
week-period: db/m and db/db mice without any treatment (i.e. untreated db/m and db/db mice). 114
Since no differences were observed between the untreated and vehicle groups, the remaining 115 protocols were performed in animals treated with vehicle or CCX832. In another set of 116 experiments, six week-old male C57BL/6J mice were maintained either on a control diet (protein 117 22%, carbohydrate 70% and fat 8% of energy, PragSolucoes, Jau, Brazil) or on a high-fat diet 118 [(HFD), protein 10%, carbohydrate 25% and fat 65% of energy, PragSolucoes] for 18 weeks. 119
Insulin sensitivity was calculated using the HOMA-IR index (Homeostasis Model 120 Assessment), which takes into account insulin and fasting blood glucose levels, using the 121 following mathematical formula: HOMA-IR = fasting insulin × fasting glucose/22.5. Additional 122 nutritional and metabolic information from the mouse models can be found in previous studies 123 (6, 7, 42) . At the end of treatment animals were maintained under anaesthesia with 2.5% 124 isoflurane for blood collection and then culled by carbon oxide (CO 2 ) inhalation. 125 were used in any protocol, parallel experiments were performed to determine the effects of the 139 inhibitor itself. Data were included in the graphics only if the inhibitor by itself produced a 140 significant effect. 141 142
Plasma Biochemistry 143
Mice were fasted for 12 h and blood was collected immediately prior to sacrifice in tubes 144 containing heparin. After collection, plasma was separated by centrifugation (2,000 rpm, 10 145 min). Plasma was aliquoted, snap frozen and storage at - First-and second-order mesenteric resistance arteries from C57BL/6J, db/m and db/db 156 mice, as well as from mice treated with a control or a HFD for 18 weeks, were cut into 2 mm 157 ring segments and mounted in a wire myograph, as previously described (16). Myograph Western blotting was developed in cultured VSMC from C57BL/6J and aorta from db/m 172 and db/db mice treated with vehicle or CCX832 as previously described (45). The mesenteric 173 arteries were not further explored for other experiments due to the limitation of the amount of 174 tissue. Briefly, tissues were homogenized in lysis buffer [(in mmol/L) sodium pyrophosphate 50, 175 NaF 50, NaCl 5, EDTA 5, EGTA 5, HEPES 10, Na 3 VO 4 2, PMSF 50, Triton 100 0.5%, and 176 leupeptin/aprotinin/pepstatin 1 mg/mL) and then sonicated for 5 sec. Proteins (50 -60 µg) 177 extracted from each lysate were separated by electrophoresis on SDS polyacrylamide gel and 178 transferred to a nitrocellulose membrane. Nonspecific binding sites were blocked with 5% milk 179 
Isolation of membrane and cytosolic fractions 191
After stimulation, VSMC were treated with ice-cold hypotonic lysis buffer (10 mmol/l 192 Tris, pH 7.4, 1.5 mmol/l MgCl 2 , 5 mmol/l KCl, 1 mmol/l DTT, 0.2 mmol/l sodium vanadate, 1 193 mmol/l PMSF, 1 g/ml aprotinin, 1 g/ml leupeptin). After passing the lysate through a 25-gauge 194 syringe needle with several rapid strokes, the samples were centrifuged at 2,000 g at 4ºC for 5 195 min. The supernatant was recentrifuged at 100,000 g at 4°C for 60 min. The pellet was 196 resuspended in lysis buffer containing 0.1% Triton X-100 and served as the membrane fraction. Paraffin sections of aorta (4 µm) were deparaffinised in xylene, rehydrated through 202 graded ethanol, and washed in water. All sections were incubated in EDTA (pH 8) and boiled for 203 15 min at 95°C for antigen unmasking. Slides were cooled to room temperature, permeabilized 204 in 0.5% Triton X-100 in PBS for 5 min, and blocked with 10% donkey serum, 1% BSA in 205
1xTBS-T for one h at room temperature in a humidified chamber. For 8-hydroxyguanosine (8-206 antibody (Abcam ab10802, 1:200) in a humidified chamber. Alexa-fluor-488-conjugated donkey 208 anti-goat secondary antibody (Molecular probes, A-11055, 1:300) was used after primary 209 antibody incubation for 1 h at room temperature in the dark. The slides were treated with 0.1% 210 Sudan Black B (Sigma Aldrich, 199664) in methanol for 10 min in order to remove lipofuscin-211 mediated autofluorescence. Nuclei were counterstained with 4-6-diamidino-2-phenylindole 212 (DAPI at 100 µg/ml) for 10 min. Sections were mounted with a coverslip using ProLong Gold 213 anti-fade mounting media containing DAPI (Molecular probes, P-36931) in the dark. 214
Fluorescence images were captured using Axiovert 200M microscope with a laser-scanning 215 module LSM 510 (Carl Zeiss AG, Heidelberg, Germany). Fluorescence quantification was 216
performed using the open-source software ImageJ (http://imagej.nih.gov/ij/) and determined by 217 the average of five different fields captured from each vessel. For negative controls, goat IgG-218 matched isotype controls were used (Santa Cruz, sc-2028). 219 220
Nitric oxide production 221
Production of nitric oxide (NO) was determined with the NO fluorescent probe diacetate 222 4-amino-5-methylamino-2',7'-difluorofluorescein diacetate (DAF-2AM -Life Technologies, 223
Carlsbad, CA, USA) as previously described (45). Endothelial cells were incubated with DAF-224 FM diacetate (5 µmol/L, 30 min) in serum free media, kept in the dark, and maintained at 37ºC. 225
Cells were washed to remove excess probe and an additional incubation for 10 min was 226 performed to allow complete de-esterification of the intracellular diacetates. Cells were 227 stimulated with chemerin (R&D Systems -0.5 ng/mL) for one hour and insulin (100 nmol/L), 228 CCX832 (10 nmol/L), N-acetyl-cysteine (NAC; 10 µmol/L) and 740Y-P (PI3K/Akt signalling 229 activator; 1 µmol/L) for 30 min. After stimulation, cells were washed with PBS and harvested by 230 mild trypsinization (trypsin -0.025%). Trypsin was inactivated with soybean trypsin inhibitor 231 (0.025%) in PBS (1:1). Additional PBS (37ºC) was added to final volume of 10 mL. Cells were 232 centrifuged for 3 min at 3,000 g. Following centrifugation, the supernatant was discarded, and 233 the cell pellet reconstituted in PBS (250 µl). 200 µl of the cell suspension was transferred to 234 black 96 well microplates (Nunc ® 436034). The DAF-FM nitrosylation was assessed by a 235 fluorimeter at excitation/emission wavelengths of 495/515 nm. Fluorescence intensity was 236 adjusted to protein concentration. 237 238 Glucose uptake measurement 239 VSMC were exposed to chemerin or vehicle, CCX832, Tiron, AICAR (AMPK signalling 240 activator; 1 mmol/L) or 740Y-P in the presence of insulin stimulation and then incubated with 241 buffer Krebs-Ringer-Hepes (15 mmol/L Hepes [pH 7.4], 105 mmol/L NaCl, 5 mmol/L KCl, 1.4 242 mmol/L CaCl 2 , 1 mmol/L KH 2 PO 4 , 1.4 mmol/L MgSO 4 and 10 mmol/L NaHCO 3 ) for 2 hours. 243
The cells were incubated with insulin (100 nmol/L) for 30 min and 0.2 mmol/L glucose 2-deoxy-244 D-glucose containing 1 µCi/ml of 2-deoxy-D-[3 H ] -glucose was added over 30 min. The buffer 245 was rapidly removed, followed by three washes with ice-cold PBS. Cells were lysed with 500 µL 246 of 0.4 mol/L NaOH for 5 min and neutralized with 500 µL of HCl. The amount of radiolabeled 247 glucose associated with the lysed cells was determined by liquid scintillation counting. To 248 control for changes in osmotic pressure, the effect of insulin on 14 C -mannitol uptake was also 249 determined. 
Chemerin decreases insulin-induced NO signalling activation in endothelial cells 272
To verify whether chemerin affects NO signalling, HMEC were exposed to chemerin (0.5 273 mg/ml) and probed for eNOS phosphorylation. Chemerin decreased basal and insulin-induced 274 eNOS phosphorylation of the active site (Ser 1177 ) ( Figure 1E ). These effects were attenuated both 275 indicating that oxidative stress mechanisms and insulin-downstream signalling are involved in 277 chemerin-induced decreased NO bioavailability, leading to endothelial dysfunction. 278
To determine whether reduced eNOS phosphorylation was associated with decreased NO 279 production, levels of NO were estimated in insulin and chemerin-stimulated HMEC. Chemerin 280 decreased NO levels in HMEC. Insulin increased NO levels in these cells and, in the presence of 281 chemerin, insulin-induced NO production was significantly reduced. This effect involves 282
ChemR23-, PI3K signalling-and ROS-dependent mechanisms since CCX832, 740Y-P and NAC 283 partially inhibited chemerin effects ( Figure 1F ). 284 285
Chemerin decreases insulin signalling in VSMC 286
In addition to its effects on endothelial cells, chemerin decreased insulin signalling in 287 VSMC. Insulin increased Akt phosphorylation in VSMC and chemerin decreased insulin-288
induced Akt phosphorylation via ChemR23 and ROS-dependent mechanisms (Figure 2A ). 289
To further investigate chemerin effects on insulin signalling, GLUT4 translocation from 290 the intracellular membrane compartments to the membrane was determined. In VSMC, chemerin 291 decreased insulin-induced GLUT4 translocation to the membrane ( Figure 2B ), which was 292 blocked by CCX832 and 740Y-P ( Figure 2B ). This suggests that ChemR23 and PI3K activation 293 is contributing to the chemerin effects on GLUT4 translocation in VSMC. 294 295
Chemerin reduces insulin-stimulated glucose uptake by VSMC 296
We evaluated the effects of chemerin on AMPK phosphorylation, another mechanism for 297 glucose uptake. Chemerin decreased AMPK phosphorylation (Thr 172 ) both in VSMC and HMEC 298 2-deoxyglucose uptake was measured in VSMC exposed to 2 μCi/ml 2-[ 3 H]DG in the presence 300 of unlabelled 2-DG. In VSMC, chemerin decreased insulin-induced glucose uptake (Figure 3 ) 301 through ROS generation, AMPK and PI3K/Akt signalling since Tiron, AICAR, CCX832 and 302 740Y-P reversed the effects of chemerin on glucose transport (Figure 3) . 303 304
ChemR23 antagonism decreases body weight and insulin and glucose levels in db/db mice 305
Since chemerin influences vascular insulin signalling, we investigated whether ChemR23 306 antagonism attenuates diabetes-related vascular dysfunction and insulin resistance. Plasma 307 chemerin levels were significantly increased in diabetic obese db/db mice ( Figure 4A ). CCX832 308 treatment slightly reduced body weight of db/db mice when compared to vehicle-treated db/db 309 mice ( Figure 4B ). In addition, CCX-treated db/db mice exhibited decreased plasma levels of 310 glucose and insulin vs. vehicle-treated db/db mice ( Figures 4C and 4D) . The HOMA index 311 indicated that CCX832 improves insulin sensitivity in db/db mice ( Figure 4E ). Increased 312 cholesterol and triglyceride levels in db/db mice were reduced by CCX832. No differences in the 313 lipid profile were observed in db/m mice treated with vehicle or CCX832 ( Figures 4F and 4G) . 314
315

CCX832 partially reverses dysfunctional insulin responses in vessels from db/db mice 316
As shown in Figure 5A , insulin-induced dilation was decreased in mesenteric arteries 317 from vehicle-treated db/db mice vs. vehicle-treated db/m mice. CCX832 treatment partially 318 improved insulin-induced vasodilation in db/db mice ( Figure 5A ). Moreover, Akt (Ser 473 ) 319 phosphorylation was reduced in aorta from vehicle-treated db/db mice vs. vehicle-treated db/m 320 treatment with CCX832 on insulin signalling. 322
Additionally, as observed in Figure 5C , increased levels of chemerin were also observed 323 in HFD-fed mice. The ChemR23 antagonist CCX832 attenuated impaired insulin-induced 324 dilatation in mesenteric arteries from HFD-fed mice ( Figure 5D ). 325
326
CCX832 reduces vascular oxidative stress in db/db mice 327
Considering that chemerin increases ROS generation (45) and that oxidative stress 328 accounted for most of the effects of chemerin upon vascular insulin signalling, we investigated 329 whether ChemR23 antagonism attenuates ROS generation in db/db mice. Diabetic mice 330
presented increased vascular levels of DNA oxidation products in comparison to vehicle-and 331 CCX832-treated db/m mice ( Figures 6A and 6B ). This was reduced by treatment of db/db mice 332 with CCX832 ( Figures 6A and 6B) . These novel findings show that the chemerin/ChemR23 axis plays a critical role in diabetes-345 associated vascular oxidative stress and altered insulin signalling. 346
Chemerin was first described as a chemoattractant agent, promoting chemotaxis of 347 leukocyte populations that express ChemR23. Later on, chemerin was associated with regulation 348
of key effectors of the glucose and lipid metabolism in mature adipocytes (11) IL-6 and MCP-1 (2, 45), an additional and potential mechanism whereby chemerin signals may 358 modulate vascular oxidative stress and altered insulin signaling. TNF-α for example has been 359 identified as a regulator of insulin sensitivity (40). In 3T3-L1 adipocytes, IL-6 reduces 360 expression of insulin receptor substrate (IRS-1) and the glucose transporter GLUT4 (36). 361
Similarly, increased levels of TNF-α reduce IRS-1 phosphorylation and decrease insulin signal 362 transduction in skeletal muscle and adipose tissue from obese rats (18). Accordingly, our data 363
show that chemerin, a pro-inflammatory adipokine, decreases insulin-induced phosphorylation of 364
Akt as well as reduces GLUT4 translocation to the membrane and insulin-induced glucose 365 uptake in VSMC from control mice. Molecular effects of chemerin in vascular insulin signalling 366 signalling and oxidative status. Together, these findings suggest that the adipokine chemerin 368 confers an insulin resistant phenotype to VSMC. 369
Corroborating our data, a recent study demonstrated that chemerin decreases glucose 370 uptake and Akt phosphorylation in insulin-stimulated cardiomyocytes (52). Inhibition of ERK1/2 371 MAPK partially prevented chemerin-induced impairment of Akt phosphorylation and glucose 372 uptake (52). In addition, Jager and colleagues have shown that interleukin-1β (IL-1β) reduces 373 insulin-induced Akt phosphorylation (Thr 308 ). Similarly, IL-1β decreases IRS-1 and Akt protein 374 expression in adipocytes, which leads to lower insulin-induced glucose uptake (19). 375
Furthermore, db/db mice treated with ChemR23 antagonist (CCX832) present a slight 376 decrease in body weight, supporting the suggestion that chemerin regulates adipogenesis via 377
ChemR23 receptor (34). However, the effects of depletion or inhibition of ChemR23 upon body 378 weight are still controversial. While Rouger et al did not observe changes in body weight or fat 379 mass in ChemR23 knockout (KO) mice (37), Ernst and colleagues showed that CMKLR1 -/mice 380 have lower food intake, total body mass, and percent of body fat compared with wild-type 381 controls (9). 382
In addition to considering ChemR23 blockade effects on body weight, it is important to 383 consider metabolic aspects, such as glucose and insulin levels. CCX832-treated db/db mice 384 exhibited a significant decrease in plasma glucose and insulin levels and HOMA index, 385 strengthening the notion that chemerin contributes to insulin resistance in this model of obesity 386 related to T2D. In addition, cholesterol and triglyceride levels in db/db mice were also reduced 387 by CCX832. Of importance, significantly increased levels of chemerin were observed both in 388 db/db and HFD-treated mice, reinforcing the idea that this adipokine is linked to glucose 389 that CMKLR1 -/mice fed with high fat diet present reduced blood glucose and serum insulin. 391
However, CMKLR1 loss is associated with glucose intolerance, which was linked to decreased 392 glucose-stimulated insulin secretion (9). On the other hand, Rouger and colleagues verified that 393 glucose tolerance was not affected in young ChemR23 knockout mice (37). 394
Classically, insulin metabolic signalling results in vasodilatation via increased NO 395 production and production of prostaglandins and endothelium-derived hyperpolarizing factors 396 (30). In addition to reducing insulin-induced vasodilatation in non-obese mice by mechanisms 397 involving PI3K/Akt pathway and oxidative stress, chemerin also reduces eNOS phosphorylation 398 (Ser 1177 ) and decreases insulin-stimulated NO production in endothelial cells, also by oxidative 399 stress-mediated events. These effects of chemerin may be directly involved in vascular insulin 400 dysfunction associated with diabetes and obesity. It has been proposed that resistance to the 401 vascular effects of insulin selectively involves the PI3K/Akt/NO signalling pathway (29). In 402 endothelial cells, blockade of the PI3K pathway induces insulin resistance, which in turn blunts 403 production of NO (28) . As demonstrated in this study, most of chemerin effects are mediated by 404
ChemR23 since its antagonism partially restores the decreased insulin-induced vasodilatation in 405 both obesity models, db/db and HFD-fed mice, and also chemerin decreases vascular Akt 406 phosphorylation in db/db mice. 407
Oxidative stress contributes to insulin resistance, particularly in skeletal muscle as well as 408 dysfunction of pancreatic β cells (12). Cellular and systemic disorders that may contribute to 409 overproduction of reactive oxygen species (ROS), including hyperglycaemia, dyslipidaemia, 410 endoplasmic reticulum (ER) stress, advanced glycation end products (AGEs), nitric oxide 411 synthase and lipid peroxides, can activate factors associated with insulin resistance (43). In 412 humans, there is a positive association between serum markers of oxidative stress and the degree 413 of insulin resistance (32). In experimental animal models, oxidative stress interrupts IRS-1 and 414 PI3K activation induced by insulin, and impairs the translocation of GLUT4 in 3T3-L1 415 adipocytes (44). In adipose tissue from healthy men with excessive caloric intake, oxidative 416 stress induces insulin resistance partially via carbonylation and oxidation-induced inactivation of 417 GLUT4 (3). Hence, increased ROS generation in vessels from db/db mice may be associated 418 with decreased insulin signalling observed in those animals. In addition, chemerin/ChemR23 419 axis may contribute to insulin resistance since ChemR23 antagonism attenuates ROS generation 420 and also restores insulin signalling in vessels from db/db mice. Furthermore, our findings clearly 421
show the involvement of oxidative stress upon chemerin-induced insulin signalling impairment 422 since antioxidants attenuate the reduced Akt phosphorylation as well as the decreased glucose 423 uptake and insulin-induced vasodilatation observed in VSMC and arteries challenged with 424
chemerin. 425
This study also demonstrates that chemerin decreases AMPK phosphorylation both in EC 426 and VSMC. AMPK is a serine-threonine kinase that has emerged as an important mediator of 427 glucose metabolism and AMPK-activating drugs are potentially useful in T2D treatment. It is 428 already established that acute AMPK activation stimulates glucose uptake by skeletal muscle via 429 both GLUT1 and GLUT4 (39). In cardiomyocytes, AMPK activation increases GLUT4 430 expression in a PKC-dependent manner (31). Moreover, AMPK activation by 5-amino-4-431
imidazole-1-β-D-carboxamide ribofuranoside (AICAR) increases heart and skeletal muscle 432 glucose uptake (27, 38) possibly by increasing GLUT4 expression (17). Most importantly, 433 overexpression of human GLUT4 gene protects db/db mice from insulin resistance and diabetes 434 (5). Similarly, our findings show that AICAR (and also PI3K/Akt activation) reverses the effects 435 of chemerin on insulin-induced glucose uptake in VSMC from normal mice, in accordance with 436 the diminished AMPK phosphorylation in response to chemerin. 437
Crosstalk between GPCRs and tyrosine kinase receptors (RTKs) is increasingly being 438 recognized as a major mechanism regulating complex signalling pathways (25). ChemR23 is an 439 G protein-coupled receptor that acts through G i to activate various intracellular signalling 440 pathways, such as ERK1/2 (49). The insulin receptor (IR) belongs to the family of RTKs, which 441 In conclusion, our data indicate that the chemerin/ChemR23 system plays an important 454 role in diabetes-associated impaired vascular insulin signalling and oxidative stress, suggesting 455 its involvement in the pathogenesis of vascular insulin resistance. Antagonism of the system 456 ameliorates vascular dysfunction and normalizes insulin signalling in a T2D animal model. 457 vascular function in obesity-associated diabetes. 459
460
PERSPECTIVES AND SIGNIFICANCE 461
Adipokines participate in many physiological processes implicated in cardiovascular 462 complications associated with obesity and diabetes. Advances in the understanding of the role 463 of adipocyte-derived factors in obesity-associated vascular dysfunction may uncover 464 mechanisms involved in adiposity-related diseases. Chemerin/ChemR23 system plays an 465 important role in diabetes-associated impaired vascular insulin signalling and oxidative stress, 466 suggesting its involvement in the pathogenesis of vascular insulin resistance. Antagonism of the 467 system ameliorates vascular dysfunction and normalizes insulin signalling in a T2D animal 468 model. We believe that targeting chemerin/ChemR23 may be an attractive therapeutic strategy to 469 improve insulin signalling and vascular function in obesity-associated diabetes. 470
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